October 2026– date –
-
Infleqtion Sqale: 30 logical qubit neutral atom computer specs
Infleqtion (Press Release) USA Overview Infleqtion announced a significant milestone, successfully achieving 30 entangled logical qubits using only 80 physical qubits on its Sqale neutral atom quantum computing platform. This breakthroug... -
Quantum Repeater Chains: Optimal entanglement routing explained
arXiv USA Overview A new arXiv preprint proposes an optimized entanglement routing method for quantum repeater chains, aiming to maximize end-to-end throughput while maintaining a fidelity threshold. This research moves beyond convention... -
France QKD Network: 100km quantum communication deployment specs
Quantum Zeitgeist France Overview France has deployed a quantum key distribution (QKD) network supporting ten users, signaling a transition of quantum communication from laboratory experiments to practical, long-duration operations. A pa... -
IBM Nighthawk r2: 120-qubit quantum advantage specs and results
Ground News USA Overview IBM's 120-qubit Nighthawk r2 superconducting quantum processor generated 1 million samples in 19 seconds during a random circuit sampling experiment, a task estimated to take the Frontier supercomputer 110 years.... -
Securecell AAV: Automated sampling for viral titer optimization
Securecell Switzerland Overview Securecell has achieved significant optimization in HEK293-based Adeno-associated virus (AAV) manufacturing processes through its automated multi-vessel sampling system, Numera. This system enabled high-fr... -
Carvykti: 5-year durable remission data for multiple myeloma
Rare Cancer News USA Overview New long-term clinical trial data from the CARTITUDE-2 study showed that 10 of 20 patients (50%) with hard-to-treat multiple myeloma remained alive and free from disease progression five years after a single... -
miv-cel CAR T-Cell: Kyverna’s 1-year benefit specs for SPS and MG
CGTlive® USA Overview Kyverna Therapeutics reported positive one-year data for mivocabtagene autoleucel (miv-cel), a CD19-directed CAR T-cell therapy, showing durable benefits in patients with Stiff Person Syndrome (SPS) and generalized ... -
AMT-130: uniQure’s 4-year Huntington’s disease progression data
pharmaphorum USA Overview uniQure announced updated four-year results from its Phase 1/2 study of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, showing a 'meaningful slowing of disease progression' in 12 patients. The ge... -
BAG3 Gene Therapy: UAB’s first Phase 1 trial timeline and specs
UAB News USA Overview The University of Alabama at Birmingham (UAB) has dosed the first patient globally in a Phase 1 gene therapy trial targeting BAG3 mutation-associated dilated cardiomyopathy (DCM). This pioneering first-in-human stud... -
CRISPR-Cas9: 1-year cholesterol reduction specs for lipid disorder
ScienceDaily (New England Journal of Medicine) USA Overview A Phase 1 clinical trial from Cleveland Clinic reported that a single infusion of a CRISPR-Cas9 gene-editing therapy led to sustained reductions in LDL cholesterol and triglycer...
